MenACWY liquid

PreclinicalBiologic

GSK

MenACWY liquid is one of 36 biologic programs targeting Gonorrhea. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GonorrheaActive, not recruiting

COVID-19Active, not recruiting

GonorrheaPreclinical

Active, not recruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Activella

Eli Lilly

Preclinical

—5

Calciferol

Alnylam Pharmaceuticals

Rayaldee

1 7

Statins

Sanofi

Preclinical

1 8

Achromycin V

WWyeth-Lederle Vaccines

Calcium

Olokizumab

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity2 trials

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Completed· GSK logo

GSK·Phase 3·NCT04707391·1,250 enrolled

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

Completed· GSK logo

GSK·Phase 2·NCT03433482·1,707 enrolled

Immune Response2 trials

Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women

Unknown status·SSwiss Federal Institute of Technology·N/A·NCT06116669·180 enrolled

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Completed· GSK logo

GSK·Phase 1/2·NCT04886154·1,440 enrolled

Vaccine1 trial

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Completed· GSK logo

GSK·Phase 2·NCT03587207·520 enrolled

COVID-191 trial

Investigating a Vaccine Against COVID-19

Completed·UUniversity of Oxford·Phase 2/3·NCT04400838·10,811 enrolled

Gonorrhea1 trial

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Completed· Pfizer logo

Pfizer··NCT05873751·1,307,378 enrolled

1 more indication

Vaccine Response1 trial

Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women

Completed·NNicole Stoffel·N/A·NCT05919472·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for MenACWY liquid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MenACWY liquid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MenACWY liquid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: GSK

MenACWY liquid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunogenicity2 trials

Immune Response2 trials

Vaccine1 trial

COVID-191 trial

Gonorrhea1 trial

Vaccine Response1 trial

References

Drug Info

Quick Facts

Related News